An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2612
Abstract: Renin–angiotensin–aldosterone system inhibitors (RAASi) are guideline‐recommended therapy for individuals with cardiorenal disease. They are associated with increased risk of hyperkalaemia, a common and life‐threatening disorder for this population. RAASi‐induced hyperkalaemia often leads to dose reduction… read more here.
Keywords: international delphi; hyperkalaemia; consensus; regarding best ... See more keywords